Prognostic factors for complete remission
. | N . | CR, % . | P . |
---|---|---|---|
Age younger than 46 y | 247 | 83.8 | .09 |
Age older than 45 y | 178 | 77 | |
FAB 2 and 4 | 225 | 84.9 | |
FAB other | 200 | 76.5 | .04 |
Performance status less than 3 | 327 | 84.4 | .001 |
Performance status higher than 2 | 97 | 69.0 | |
WBC count lower than 30 × 109/L | 281 | 86.5 | < .0001 |
WBC count higher than 30 × 109/L | 144 | 75.4 | |
Karyotype | < .0001 | ||
Normal | 180 | 82.2 | |
Good | 64 | 96.9 | |
Intermediate | 61 | 67.2 | |
Poor | 59 | 69.5 | |
Rh123 efflux positive | 54 | 65.4 | .04 |
Rh123 efflux negative | 106 | 81.3 | |
mdr gene positive | 76 | 82.9 | NS |
mdr gene negative | 188 | 83.8 | |
UIC2 positive | 77 | 80.6 | NS |
UIC2 negative | 160 | 78.8 | |
4E3 positive | 62 | 83.7 | NS |
4E3 negative | 169 | 76.3 | |
Quinine dose reduction | 79 | 80.2 | NS |
No quinine dose reduction | 134 | 81.8 |
. | N . | CR, % . | P . |
---|---|---|---|
Age younger than 46 y | 247 | 83.8 | .09 |
Age older than 45 y | 178 | 77 | |
FAB 2 and 4 | 225 | 84.9 | |
FAB other | 200 | 76.5 | .04 |
Performance status less than 3 | 327 | 84.4 | .001 |
Performance status higher than 2 | 97 | 69.0 | |
WBC count lower than 30 × 109/L | 281 | 86.5 | < .0001 |
WBC count higher than 30 × 109/L | 144 | 75.4 | |
Karyotype | < .0001 | ||
Normal | 180 | 82.2 | |
Good | 64 | 96.9 | |
Intermediate | 61 | 67.2 | |
Poor | 59 | 69.5 | |
Rh123 efflux positive | 54 | 65.4 | .04 |
Rh123 efflux negative | 106 | 81.3 | |
mdr gene positive | 76 | 82.9 | NS |
mdr gene negative | 188 | 83.8 | |
UIC2 positive | 77 | 80.6 | NS |
UIC2 negative | 160 | 78.8 | |
4E3 positive | 62 | 83.7 | NS |
4E3 negative | 169 | 76.3 | |
Quinine dose reduction | 79 | 80.2 | NS |
No quinine dose reduction | 134 | 81.8 |
NS indicates not significant.